Christen Shoesmith

C_Shoesmith

Working Group Member

Associate Professor, Neurology, Western University; Neuromuscular Neurologist, Director of Neuromuscular Fellowships and Motor Neuron Diseases Clinic, London Health Sciences Centre

Medical Director, Motor Neuron Diseases Clinic, University Hospital in London


NMD4C Involvement: Pillar 2: Clinical Research, Pillar 3: Clinical Practice Research

Research Interests: Amyotrophic lateral sclerosis, spinal muscular atrophy, primary lateral sclerosis, neurological complications of pregnancy

Twitter profile

Biography

Dr. Shoesmith earned her Bachelor of Science degree from the University of Winnipeg in 1996 and her MD from the University of Manitoba in 2000. She completed her neurology residency at Western University in 2005. From 2005 to 2007, Dr. Shoesmith completed a neuromuscular clinical fellowship with a specific focus on treatment and care of ALS patients at Western University. In 2007, Dr. Shoesmith joined the neurology faculty at the London Health Sciences Centre as a neuromuscular neurologist. She also has a general neuromuscular clinic and an EMG clinic. In 2010, Dr. Shoesmith became the Motor Neuron Diseases Clinic Director at LHSC. She is the site principal investigator for all ALS clinical trials run at LHSC.

Dr. Shoesmith is actively involved in teaching of residents and medical students. She is the neuromuscular education coordinator for residents and fellows. She is also a co-director of the neurosciences curriculum for medical students at the Schulich School of Medicine & Dentistry.

Within the NMD4C, Dr. Shoesmith is a part of the Curriculum Development working group.


Recent Publications

Shefner, JM, Cudkowicz, ME, Genge, A, Hardiman, O, Al-Chalabi, A, Andrews, JA et al.. Reldesemtiv in Amyotrophic Lateral Sclerosis: Results From the COURAGE-ALS Randomized Clinical Trial. JAMA Neurol. 2025. PMID:40126464

Pottinger, TD, Motelow, JE, Povysil, G, Moreno, CAM, Ren, Z, Phatnani, H et al.. Rare variant analyses validate known ALS genes in a multi-ethnic population and identifies ANTXR2 as a candidate in PLS. BMC Genomics. 2024.25 (1)651 PMID:38951798

Trudel, P, Quesnel-Olivo, MH, Blais, M, Shoesmith, C, Dupré, N. ALS, MAiD and Tissue Donation: Case Reports from Six Patients' Care Journeys. Can J Neurol Sci. 2024. 1-2 PMID:38835198

Benatar, M, Hansen, T, Rom, D, Geist, MA, Blaettler, T, Camu, W et al.. Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Neurol. 2024.23 (7)687-699 PMID:38782015

Ozzoude, M, Varriano, B, Beaton, D, Ramirez, J, Adamo, S, Holmes, MF et al.. White matter hyperintensities and smaller cortical thickness are associated with neuropsychiatric symptoms in neurodegenerative and cerebrovascular diseases. Alzheimers Res Ther. 2023.15 (1)114 PMID:37340319

Riek, HC, Brien, DC, Coe, BC, Huang, J, Perkins, JE, Yep, R et al.. Cognitive correlates of antisaccade behaviour across multiple neurodegenerative diseases. Brain Commun. 2023.5 (2)fcad049 PMID:36970045

Kapustin, D, Zarei, S, Wang, W, Binns, MA, McLaughlin, PM, Abrahao, A et al.. Neuropsychiatric Symptom Burden across Neurodegenerative Disorders and its Association with Function. Can J Psychiatry. 2023.68 (5)347-358 PMID:36637224

Shoesmith, C. Palliative care principles in ALS. Handb Clin Neurol. 2023.191 139-155 PMID:36599506

Mitsumoto, H, Jang, G, Lee, I, Simmons, Z, Sherman, AV, Heitzman, D et al.. Primary lateral sclerosis natural history study - planning, designing, and early enrollment. Amyotroph Lateral Scler Frontotemporal Degener. 2023.24 (5-6)394-404 PMID:36576200

Samra, K, MacDougall, AM, Peakman, G, Bouzigues, A, Bocchetta, M, Cash, DM et al.. Motor symptoms in genetic frontotemporal dementia: developing a new module for clinical rating scales. J Neurol. 2023.270 (3)1466-1477 PMID:36385202

See more on PubMed